Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Pilot of Osanetant to Reduce Testosterone in Men With Adenocarcinoma of the Prostate (PORT-MAP)

NCT05607342 is registered in ClinicalTrials.gov with University of Kansas Medical Center as lead sponsor.

NCT NCT05607342
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05607342 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Pilot of Osanetant to Reduce Testosterone in Men With Adenocarcinoma of the Prostate (PORT-MAP)
Lead sponsor
University of Kansas Medical Center
Phase
Phase 1
Overall status
Terminated
Start date
January 3, 2023
Completion date
November 6, 2023
Enrollment
1 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

prostate adenocarcinoma